Nasdaq warns enVVeno Medical (NVNBW) on sub-$1 bid, sets cure deadline

Rhea-AI Filing Summary

enVVeno Medical Corporation reported that it received a notice from Nasdaq on October 7, 2025 stating that the company no longer meets the Nasdaq Capital Market’s minimum bid price requirement because its common stock closed below $1.00 per share for 30 consecutive business days. The notice does not immediately affect the stock’s Nasdaq listing.

The company has 180 calendar days, until April 6, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least 10 consecutive trading days, a period Nasdaq may extend beyond 10 days at its discretion. If it still does not comply by that date, enVVeno may qualify for an additional 180-day period if it meets other Nasdaq initial listing standards and notifies Nasdaq of its plan to cure the deficiency, potentially including a reverse stock split. If Nasdaq ultimately determines compliance cannot be regained, the company’s stock could be delisted, although enVVeno would have the right to appeal.

Positive

• None.

Negative

• Nasdaq minimum bid-price deficiency and delisting risk: enVVeno received a Nasdaq notice that its stock traded below $1.00 for 30 consecutive business days, triggering noncompliance with Nasdaq Capital Market listing Rule 5550(a)(2) and creating the possibility of delisting if compliance is not regained within the allowed periods.

Insights

Equity & Listing Standards Analyst

Nasdaq bid-price noncompliance introduces listing risk if not cured.

enVVeno Medical Corporation has been notified that its stock no longer satisfies Nasdaq’s minimum bid price rule after trading below $1.00 for 30 consecutive business days. This places the company in a formal deficiency status under Nasdaq Listing Rule 5550(a)(2), although there is no immediate change to its Nasdaq Capital Market listing.

The company has an initial 180-day window, until April 6, 2026, to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive trading days, with Nasdaq able to extend that trading-day requirement. If it fails by that date but meets other initial listing standards and market value requirements, it may access a second 180-day period by committing in writing to cure the issue, potentially via a reverse stock split.

If enVVeno does not meet the criteria for an extension or cannot demonstrate a viable cure plan, Nasdaq may move to delist the shares. The company would then have appeal rights, during which the stock would remain listed until that process is completed. Actual outcomes will depend on the company’s actions and future bid-price performance.

8-K Event Classification

2 items: 3.01, 9.01

2 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001661053 0001661053 2025-10-07 2025-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2025

enVVeno Medical Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-38325		33-0936180
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

70 Doppler

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

(949) 261-2900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		NVNO		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On October 7, 2025, enVVeno Medical Corporation (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of Nasdaq Listing Rules.

Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until April 6, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must close at or above $1.00 per share for a minimum of 10 consecutive trading days (which period may be extended to greater than 10 consecutive trading days at the sole discretion of Nasdaq) prior to April 6, 2026.

In the event the Company does not regain compliance by April 6, 2026, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify for the additional 180-day period, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the Nasdaq Capital Market until the completion of the appeal process.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVVENO MEDICAL CORPORATION
Dated: October 10, 2025	/s/ Robert A. Berman
	Robert A. Berman
	Chief Executive Officer

FAQ

What Nasdaq notification did enVVeno Medical Corporation (NVNBW) receive?

On October 7, 2025, enVVeno Medical Corporation received a notice from Nasdaq that its common stock no longer complies with the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) because the closing bid price was below $1.00 per share for 30 consecutive business days.

Does the Nasdaq bid-price notice immediately affect enVVeno Medical’s listing?

No. The company states that Nasdaq’s notice has no immediate effect on the listing of its common stock on the Nasdaq Capital Market. The shares continue to trade while the company works within the compliance period.

How long does enVVeno Medical have to regain Nasdaq bid-price compliance?

enVVeno Medical has 180 calendar days from the October 7, 2025 notice, or until April 6, 2026, to regain compliance. To do so, its common stock must close at or above $1.00 per share for at least 10 consecutive trading days, a period Nasdaq may extend at its sole discretion.

Can enVVeno Medical get more time beyond April 6, 2026 to meet Nasdaq’s bid-price rule?

Yes. If the company does not regain compliance by April 6, 2026, it may qualify for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial Nasdaq Capital Market listing standards apart from bid price, and if it notifies Nasdaq in writing of its intention to cure the deficiency, potentially including a reverse stock split.

What happens if enVVeno Medical cannot regain Nasdaq compliance?

If Nasdaq staff determines that enVVeno Medical cannot cure the bid-price deficiency or is not eligible for an additional 180-day period, Nasdaq may notify the company that its common stock is subject to delisting. The company would have the right to appeal any delisting determination, and its stock would remain listed on the Nasdaq Capital Market until the appeal process is completed.

Is enVVeno Medical considering a reverse stock split to address the Nasdaq issue?

The disclosure states that, to obtain a potential second 180-day compliance period, the company must notify Nasdaq of its intention to cure the deficiency during that period, which may include effecting a reverse stock split, if necessary. The document does not state that a reverse split has been approved or implemented.